Goldman Sachs Downgrades Valeant After Market's Loss of Confidence

"We have less confidence the market will reward the stock anytime soon," the number two-rated analyst on Valeant says.

Ackman Defends Valeant, Wall Street Unloads Stocks

Goldman Sachs is throwing in the towel on Valeant Pharmaceuticals.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.